8-K: Jasper Therapeutics Reports Positive Asthma Data, Resolves BEACON Study Anomaly

Jasper Therapeutics announced positive preliminary Phase 1b data for briquilimab in allergic asthma and concluded its internal investigation into anomalous BEACON study results, attributing them to patient selection issues.

Summary

• Jasper Therapeutics reported positive preliminary clinical data from its ETESIAN Phase 1b study of subcutaneous briquilimab in adult participants with allergic asthma.
• A single 180mg dose of briquilimab demonstrated substantial reductions in sputum eosinophils at both 6 and 12 weeks, and improvements in FEV1 in Early Asthmatic Response (EAR) and Late Asthmatic Response (LAR).
• Significant reductions in serum tryptase were observed, consistent with other briquilimab studies, and the drug was well tolerated with a favorable safety profile.
• The company completed its internal investigation into the anomalous lack of clinical response observed in the July 2025 BEACON data for CSU cohorts 8 and 9.
• The investigation concluded that the unexpected efficacy results in US patients were not due to drug product issues but likely patient selection problems, as 9 of 10 non-responding patients did not appear to have mast cell-driven Chronic Spontaneous Urticaria (CSU).
• Pharmacokinetic (PK) and pharmacodynamic (PD) measures, including deep reductions in tryptase levels, remained consistent across BEACON cohorts and after switching to a new drug lot, supporting the drug product's integrity.
• A panel of CSU Key Opinion Leaders (KOLs) reviewed the findings and provided recommendations for future patient selection, including utilizing sites with certified immunologists/dermatologists and expanded patient history review.

Sentiment

Score: 8

Explanation: The positive preliminary data for briquilimab in asthma represents a significant new opportunity and proof of concept for the drug's mechanism. The successful conclusion of the BEACON investigation, attributing prior anomalous results to patient selection rather than drug issues, removes a major uncertainty and validates the drug's quality and mechanism. These are strong positive developments, despite the early stage of the asthma program and the need for further data in CSU.

Positives

• Briquilimab demonstrated positive preliminary clinical data in the ETESIAN Phase 1b study for allergic asthma, showing proof of concept for mast cell depletion in this indication.
• A single 180mg dose of briquilimab led to substantial reductions in sputum eosinophils at 6 and 12 weeks, and improvements in FEV1 for both Early Asthmatic Response (EAR) and Late Asthmatic Response (LAR).
• Significant reductions in serum tryptase were observed, indicating consistent biologic activity of briquilimab.
• Briquilimab was well tolerated in the ETESIAN study, exhibiting a favorable safety profile with infrequent and low-grade adverse events.
• The internal investigation into the anomalous BEACON study results concluded that there were no issues with the drug product or study conduct, alleviating concerns about drug quality.
• The BEACON investigation identified patient selection issues as the likely cause for the lack of response in 9 out of 10 US patients, providing clear actionable insights for future trials.
• Pharmacokinetic and pharmacodynamic responses in BEACON study patients remained consistent, even in non-responders, further supporting the drug's mechanism of action and integrity.

Negatives

• The July 2025 BEACON data for CSU cohorts 8 and 9 showed an anomalous lack of clinical response in 10 US patients, with none achieving Complete Response or Well Controlled UAS7 by week 12.
• The ETESIAN study was terminated early for administrative reasons, though preliminary data was still reported.

Risks

• General economic, political, and business conditions could adversely affect operations.
• Product candidates may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.
• Clinical trials may not confirm any safety, potency, or other product characteristics described or assumed.
• Prior test, study, and trial results, including preliminary results for the ETESIAN study, may not be replicated in continuing or future studies and trials.
• Inability to raise capital to continue operations and the BEACON study.
• Inability to successfully market or gain market acceptance of product candidates.
• Product candidates may not be beneficial to patients or successfully commercialized.
• Patients' willingness to try new therapies and physicians' willingness to prescribe these therapies may be limited.
• Effects of competition on the business.
• Third parties on which the company depends for laboratory, clinical development, manufacturing, and other critical services may fail to perform satisfactorily.
• Business, operations, clinical development plans and timelines, and supply chain could be adversely affected by health epidemics.
• Inability to obtain and maintain sufficient intellectual property protection for investigational products or infringing the intellectual property protection of others.

Future Outlook

Jasper Therapeutics plans further development of briquilimab in asthma, including potential dose-ranging/repeat dose studies. The company expects to release the last wave of BEACON data in Q1 2026, which will inform dose selection for the Phase 2b CSU study planned to commence mid-2026. Multi-dose data for Chronic Inducible Urticaria (CIndU) is also anticipated in a Q1 2026 data update. The company is confident that learnings from the BEACON investigation will help minimize enrollment of non-mast cell-driven CSU patients in future trials.

Management Comments

• Dr. Elliot Israel, Director of Clinical Research in the Pulmonary and Critical Care Division at the Brigham and Women's Hospital, stated, 'I am pleased to see the initial results of the ETESIAN study, the first clinical study to evaluate an agent specifically targeting mast cells in asthma patients... The initial results demonstrate the potential to reduce both airway hyperresponsiveness and the accumulation of eosinophils in the airways, both of which are key factors in managing chronic asthma and reducing exacerbations. Given that a substantial portion of asthma patients remain underserved by currently approved therapies, depleting mast cells through KIT inhibition may represent an intriguing new treatment option for patients with chronic asthma.'
• Dr. Daniel Adelman, Acting Chief Medical Officer of Jasper, commented, 'We are very pleased to present the positive preliminary data from the ETESIAN study, which demonstrates proof of concept for mast cell depletion using briquilimab as a potential therapeutic option for patients with asthma... These data, combined with the favorable safety profile observed in the ETESIAN study and in other briquilimab clinical studies, provide a strong rationale for further development of briquilimab in asthma.'
• Dr. Martin Metz, Professor of Dermatology and Allergy Charité – Universitätsmedizin Berlin and member of the KOL panel, remarked, 'I commend the Jasper team for the professional manner in which they managed the anomalous results received in July, by promptly notifying clinical sites and conducting a thorough investigation into the root cause... While it appears that 9 of the 10 patients enrolled in the US sites likely did not have mast cell-driven CSU, their data still provide valuable insights into the pharmacodynamics and the safety profile of briquilimab. I'm very encouraged with the overall profile of briquilimab to date, and I look forward to seeing additional data in early 2026.'
• Ronald Martell, President and Chief Executive Officer of Jasper, stated, 'We are very pleased to be able to close out our internal investigation of the anomalous results seen in the BEACON data released in July... Going forward, we are confident that the learnings from this investigation and the recommendations from our KOLs will help us minimize the enrollment of patients that may not have mast cell-driven disease. Most importantly, we are very pleased that the internal investigation demonstrated that there were no issues with the drug product utilized in the study, and we are looking forward to the last wave of BEACON data expected in Q1 2026 that will enable us to select final doses for the Phase 2b CSU study, planned to commence mid-2026.'

Industry Context

This announcement positions briquilimab as a potentially novel therapeutic option for chronic asthma, an area where a substantial portion of patients remain underserved by existing therapies. The focus on mast cell depletion through KIT inhibition represents a distinct mechanism of action compared to many current asthma treatments. For Chronic Spontaneous Urticaria (CSU), the resolution of the BEACON study's anomalous results, attributing them to patient selection rather than drug efficacy or quality, helps to restore confidence in briquilimab's potential in this mast cell-driven disease, aligning with the broader industry trend of precision medicine and targeted therapies.

Comparison to Industry Standards

• Briquilimab is highlighted as the first clinical study to evaluate an agent specifically targeting mast cells in asthma patients, suggesting a novel approach compared to existing therapies.
• The filing notes that a substantial portion of asthma patients remain underserved by currently approved therapies, indicating a market need that briquilimab aims to address.
• While no specific comparable companies or projects are named, the mechanism of KIT inhibition for mast cell depletion positions briquilimab uniquely in the treatment landscape for both asthma and urticaria, which are often treated with corticosteroids, bronchodilators, or biologics like omalizumab (Xolair) or dupilumab (Dupixent) for asthma, and antihistamines or omalizumab for CSU.

Stakeholder Impact

• Shareholders: Positive preliminary asthma data and the resolution of the BEACON investigation could lead to increased investor confidence and potential share price appreciation.
• Patients (Asthma): Briquilimab offers a potential new treatment option for chronic asthma, particularly for those underserved by current therapies, by targeting mast cells.
• Patients (CSU): The clarification regarding the BEACON study's anomalous results helps maintain confidence in briquilimab's potential for CSU patients, with future studies expected to improve patient selection.
• Employees: Continued positive clinical development and strategic clarity provide stability and direction for the company's workforce.
• Regulatory Authorities: The detailed investigation and transparent reporting demonstrate adherence to clinical and regulatory standards, potentially fostering trust.

Next Steps

• Evaluate next steps for further development of briquilimab in chronic asthma, including potential dose-ranging/repeat dose studies.
• Present additional BEACON and Open Label Extension (OLE) data in Q1 2026 to enable Phase 2b dose selection for CSU.
• Commence the Phase 2b CSU study, planned for mid-2026.
• Provide a Q1 2026 data update including multi-dose data for Chronic Inducible Urticaria (CIndU).

Key Dates

Recommendation

The positive preliminary Phase 1b data for briquilimab in allergic asthma represents a significant expansion of the drug's potential, opening up a large, underserved market. This proof of concept for a novel mast cell-targeting mechanism in asthma is a strong value driver. Furthermore, the successful conclusion of the BEACON study investigation, which definitively ruled out drug product issues and attributed prior anomalous results to patient selection, removes a major overhang and validates the drug's integrity and mechanism in CSU. While both programs are still in development, these combined updates significantly de-risk the asset and expand its addressable market, making it an attractive 'buy' for long-term investors willing to accept clinical development risks.

Keywords

Briquilimab, Asthma, Chronic Spontaneous Urticaria, CSU, KIT inhibition, Mast cell depletion, Clinical trial data, Phase 1b, ETESIAN study, BEACON study, Biotechnology, Drug development, Allergic asthma, Eosinophils, FEV1, Serum tryptase, Pharmacodynamics, Safety profile